DK1531800T3 - Stealth-lipidnanokapsler, fremgangsmåder til fremstilling deraf som en bærer for aktivt princip(per) - Google Patents

Stealth-lipidnanokapsler, fremgangsmåder til fremstilling deraf som en bærer for aktivt princip(per)

Info

Publication number
DK1531800T3
DK1531800T3 DK03757174.2T DK03757174T DK1531800T3 DK 1531800 T3 DK1531800 T3 DK 1531800T3 DK 03757174 T DK03757174 T DK 03757174T DK 1531800 T3 DK1531800 T3 DK 1531800T3
Authority
DK
Denmark
Prior art keywords
nanocapsules
lipid
preparation
lipid nanocapsules
methods
Prior art date
Application number
DK03757174.2T
Other languages
English (en)
Inventor
Didier Hoarau
Pascal Delmas
Jean-Christophe Leroux
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Priority claimed from PCT/IB2003/003213 external-priority patent/WO2003103822A2/en
Application granted granted Critical
Publication of DK1531800T3 publication Critical patent/DK1531800T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
DK03757174.2T 2002-06-11 2003-06-11 Stealth-lipidnanokapsler, fremgangsmåder til fremstilling deraf som en bærer for aktivt princip(per) DK1531800T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0207175A FR2840532B1 (fr) 2002-06-11 2002-06-11 Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
US42111202P 2002-09-09 2002-09-09
PCT/IB2003/003213 WO2003103822A2 (en) 2002-06-01 2003-06-11 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)

Publications (1)

Publication Number Publication Date
DK1531800T3 true DK1531800T3 (da) 2011-07-11

Family

ID=29559140

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03757174.2T DK1531800T3 (da) 2002-06-11 2003-06-11 Stealth-lipidnanokapsler, fremgangsmåder til fremstilling deraf som en bærer for aktivt princip(per)

Country Status (5)

Country Link
US (1) US20040076683A1 (da)
AT (1) ATE511834T1 (da)
DK (1) DK1531800T3 (da)
ES (1) ES2366978T3 (da)
FR (1) FR2840532B1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
FR2916974B1 (fr) 2007-06-11 2010-11-26 Univ Angers Procede de preparation de nanoparticules lipidiques
FR2916973B1 (fr) 2007-06-11 2010-02-26 Univ Angers Nanocapsules a coeur lipidique chargees en actif(s) hydrosoluble(s) ou hydrodispersible(s)
FR2939699B1 (fr) 2008-12-12 2011-05-06 Univ Angers Procede de preparation de nanoparticules lipidiques
WO2011085354A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
AU2012245080B2 (en) 2011-04-20 2015-06-25 The University Of Sydney A method for the treatment of a solid tumour
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US20240148873A1 (en) 2012-12-13 2024-05-09 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
FR3017294B1 (fr) * 2014-02-07 2021-10-01 Atlangram Nanoparticules lipidiques comprenant un antibiotique et leurs utilisations en therapie
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017139623A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
EP3448260A4 (en) 2016-04-27 2019-10-09 Immunomedics, Inc. EFFICACY OF ANTI-TROP-2 SN-38 ANTIBODY CONJUGATES FOR THE THERAPY OF REZIDIVATED / REFRACTORY TUMORS AGAINST CHECKPOINT INHIBITORS
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
CN110352201A (zh) 2017-04-03 2019-10-18 免疫医疗公司 用于癌症疗法的抗体药物缀合物的皮下施用
JP7355394B2 (ja) * 2018-05-03 2023-10-03 エル．イー．エー．エフ． ホールディングス グループ エルエルシー カロテノイド組成物およびその使用
EP3679928A1 (fr) 2019-01-08 2020-07-15 Atlangram Composition pharmaceutique de type gel pour traiter/prevenir une infection
FR3099069A1 (fr) * 2019-07-24 2021-01-29 Université D`Angers Procede continu de nano-emulsification par inversion de phase en concentration
WO2021207690A1 (en) 2020-04-09 2021-10-14 L.E.A.F. Holdings Group Llc Trans-crocetin compositions and treatment regimens
WO2022025997A1 (en) * 2020-07-27 2022-02-03 L.E.A.F. Holdings Group Llc Trans-crocetin compositions and treatment regimens

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5160669A (en) * 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
EP3015101B1 (en) * 2005-10-03 2019-08-21 PINSKY, Mark A. Non-phospholipid liposomes comprising hyaluronic acid

Also Published As

Publication number Publication date
FR2840532B1 (fr) 2005-05-06
FR2840532A1 (fr) 2003-12-12
ATE511834T1 (de) 2011-06-15
ES2366978T3 (es) 2011-10-27
US20040076683A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
FR2840532B1 (fr) Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
FI3173073T3 (fi) Liposomeja lääkkeen antamiseen
CA2468916A1 (en) A stable oxaliplatin solution formulation
CY1109364T1 (el) Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
BR0010612A (pt) Vacinas
CR7776A (es) Conjugados de polimero con antigenicidad disminuida, metodos de preparacion y usos de los mismos
AU2003221291A1 (en) Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
WO2000062813A3 (en) Cationic peg-lipids and methods of use
WO2003043631A3 (en) Method for identification of tumor targeting enzymes
CY1120462T1 (el) Τοπικες ανθελμινθικες κτηνιατρικες τυποποιησεις
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
JP2001247459A5 (da)
NO20050347L (no) Flytende legemidler i oral farmasoytisk form med bedret biotilgjengelighet
SG148997A1 (en) Powders comprising low molecular dextran and methods of producing those powders
WO2002053100A3 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
JP6482570B2 (ja) 経皮吸収促進剤及び経皮吸収促進助剤
NO20050153L (no) Stealth-nanokapsler, fremgangsmater for fremstilling derav og anvendelse som en baerer for aktivt prinsipp/aktive prinsipper
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
JP2022169627A (ja) 腋臭を治療する方法
CN101015525A (zh) 紫杉醇脂质体及其制备方法
JP2000159790A5 (da)
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
WO2006065888A3 (en) Targeted iron chelator delivery system